Global Gastric Cancer Market to Witness Steady Growth by Upcoming Decade – BIS Research

Precision oncology approaches, where therapies are tailored to molecular profiles such as HER2 positivity, MSI-H, and PD-L1 expression, are shaping the treatment landscape. Minimally invasive surgery and advanced radiotherapy are also improving recovery and long-term survival. 

What is a Gastric Cancer? 

Gastric cancer is a malignancy that develops in the lining of the stomach. It remains one of the most common causes of cancer-related mortality globally. Risk factors include Helicobacter pylori infection, genetic predisposition, dietary habits, and age. Early detection is crucial for improving outcomes, but most cases are diagnosed at an advanced stage, especially in developing countries. 

What is the Current Market Outlook for Gastric Cancer? 

Asia-Pacific accounts for the largest patient population, while North America leads in adoption of advanced therapies. Immunotherapy and targeted therapy are projected to contribute the majority of treatment revenue by 2035, while chemotherapy’s share is expected to decline gradually as combination and personalized regimens expand. Continuous innovations in biologics, immunotherapies, surgical techniques, and radiotherapy are expected to fuel market growth. 

What is the key Innovation & Trends in Gastric Cancer Market? 

• Biomarker-driven diagnostics improve patient stratification and treatment efficacy. 
• Rising use of combination regimens integrating chemotherapy with immunotherapy. 
• Development of precision medicine approaches targeting HER2, PD-L1, and MSI-H. 
• Minimally invasive surgical techniques and advanced radiotherapy improving recovery. 
• Collaborations and licensing agreements between pharma and biotech companies accelerating commercialization. 

How Does This Report Help Organizations Drive Strategic Growth? 

• Benchmark therapy options – Compare chemotherapy, targeted therapies, immunotherapies, and combination regimens. 
• Evaluate innovation pipelines – Track clinical trials, biomarker-driven therapies, and immunotherapy advancements. 
• Identify regional opportunities – Assess therapy adoption, screening programs, and healthcare infrastructure globally. 
• Monitor competitive strategies – Review collaborations, licensing agreements, and clinical success rates. 
• Navigate market barriers – Address cost, accessibility, and late-stage diagnosis challenges. 

Explore More on Complete TOC or Book a Preview  

What Are the Demand Driver and Challenges in Gastric Cancer Market? 

Drivers 

• Rising global gastric cancer prevalence, particularly in Asia-Pacific and Europe. 
• Growing awareness of screening and early detection programs. 
• Innovation in targeted therapies and immunotherapies improving survival outcomes. 
• Adoption of precision oncology for molecular profile-guided treatments. 
• Minimally invasive surgical and radiotherapy techniques enhancing recovery. 
• Strategic pharma-biotech collaborations accelerating therapy development. 

Challenges 

• Late-stage diagnosis in developing regions. 
• High treatment costs limit patient access. 
• Variability in treatment response across populations. 
• Disparities in availability of novel therapies in emerging markets. 
• Need for region-specific treatment strategies to address clinical practices. 

What is the Market Segmentation in the Gastric Cancer Market? 

By Treatment Type 

• Chemotherapy  

• Targeted Therapy  

• Immunotherapy  

• Radiotherapy  

• Surgery 

• Others 

By End User 

• Hospitals  

• Specialty Cancer Centers  

• Others  

By Region 

• North America 

• Europe 

• Asia-Pacific 

What Is the Competitive Landscape in the Gastric Cancer Market? 

Key Players 

•    Daiichi Sankyo, Inc. 

•    AstraZeneca 

•    F. Hoffmann-La Roche Ltd 

•    Merck & Co., Inc. 

•    Eli Lilly and Company 

•    Pfizer 

•    BeOne Medicines 

•    Zymeworks Inc. 

•    Bristol Myers Squibb 

Strategic Initiatives 

• Development of checkpoint inhibitors, HER2-targeted drugs, and VEGF inhibitors. 
• Active clinical trial programs for combination and targeted therapies. 
• Collaborations and licensing agreements accelerate drug development. 
• Focus on biomarker-driven treatment personalization. 

Here Are Some Case Studies and Success Stories in Gastric Cancer Market 

• Asia-Pacific: Strong adoption of immunotherapy and biomarker-guided treatments, particularly in Japan, South Korea, and China. 
• North America: Leading role in clinical trial adoption for combination regimens and advanced immunotherapies. 
• Europe: Emerging adoption of targeted therapies and precision oncology in hospitals and specialty cancer centers. 

[Schedule a Call with Industry Experts] 

[Download Complete TOC] 

Related Reports from BIS Research 

Hormone Sensitive Advanced Prostate Cancer Market                    

Non-Small Cell Lung Cancer Market               

Non-Metastatic Prostate Cancer Market                      

About BIS Research 

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.   

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.    

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.  

Contact 

Head of Marketing   

Email: media@bisresearch.com    

BIS Research Inc.   

39111 PASEO PADRE PKWY STE 313,   

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights   

Get Expert Insights @https://community.insightmonk.com    

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research    

Connect with us on Twitter@ https://twitter.com/BISResearch 

Connect with us on Medium@ https://medium.com/@faisal.bis 

Connect with us on YouTube@ https://www.youtube.com/@BISResearchInc